Edition:
India

AB Science Announces Negative Opinion From CHMP


Thursday, 19 Apr 2018 

April 19 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT THE CHMP HAS ADOPTED A NEGATIVE OPINION FOR THE MARKETING AUTHORIZATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS.AB SCIENCE WILL PROVIDE ADDITIONAL DATA THROUGH A REEXAMINATION PROCEDURE.RE-EXAMINATION WILL LEAD CHMP TO DELIVER A SECOND OPINION IN JULY 2018.REAFFIRMS ITS COMMITMENT TO CARRY OUT DEVELOPMENT OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS.